Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice by Sun, Jian-feng et al.
 
Effects of ATPM-ET, a novel κ agonist with partial μ activity, on
physical dependence and behavior sensitization in mice
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Sun, J., Y. Wang, F. Li, G. Lu, Y. Tao, Y. Cheng, J. Chen, et al.
2010. “Effects of ATPM-ET, a novel κ agonist with partial μ
activity, on physical dependence and behavior sensitization in
mice.” Acta Pharmacologica Sinica 31 (12): 1547-1552.
doi:10.1038/aps.2010.164.
http://dx.doi.org/10.1038/aps.2010.164.
Published Version doi:10.1038/aps.2010.164
Accessed February 16, 2015 11:18:33 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987362
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAActa Pharmacologica Sinica  (2010) 31: 1547–1552 
© 2010 CPS and SIMM    All rights reserved 1671-4083/10  $32.00
www.nature.com/aps
npg
Effects of ATPM-ET, a novel κ agonist with partial μ 
activity, on morphine-induced physical dependence 
and behavior sensitization in mice
Jian-feng SUN
1, Yu-hua WANG
2, Fu-ying LI
1, Gang LU
1, Yi-min TAO
1, Yun CHENG
1, Jie CHEN
1, Xue-jun XU
1, Zhi-qiang CHI
1, 
John L NEUMEYER
3, Ao ZHANG
1, *, Jing-gen LIU
1, * 
1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese 
Academy of Sciences, Shanghai 201203, China; 
2School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210046, 
China; 
3Alcohol & Drug Abuse Research Center, McLean Hospital, Harvard Medical School, MA 02478, USA
 
Aim: To investigate the effects of ATPM-ET [(–)-3-N-Ethylaminothiazolo [5,4-b]-N-cyclopropylmethylmorphinan hydrochloride] on physical 
dependence and behavioral sensitization to morphine in mice.  
Methods: The pharmacological profile of ATPM-ET was characterized using competitive binding and GTPγS binding assays.  We then 
examined the antinociceptive effects of ATPM-ET in the hot plate test.  Morphine dependence assay and behavioral  sensitization assay 
were used to determine the effect of ATPM-ET on physical dependence and behavior sensitization to morphine in mice.  
Results: The binding assay indicated that ATPM-ET ATPM-ET exhibited a high affinity to both κ- and µ-opioid receptors with Ki  values 
of 0.15 nmol/L and 4.7 nmol/L, respectively, indicating it was a full κ-opioid receptor agonist and a partial μ-opioid receptor agonist.  
In the hot plate test, ATPM-ET produced a dose-dependent antinociceptive effect, with an ED50 value of 2.68 (2.34–3.07) mg/kg.     
Administration of ATPM-ET (1 and 2 mg/kg, sc) prior to naloxone (3.0 mg/kg, sc) injection significantly inhibited withdrawal jumping 
of mice.  In addition, ATPM-ET (1 and 2 mg/kg, sc) also showed a trend toward decreasing morphine withdrawal-induced weight loss. 
ATPM-ET (1.5 and 3 mg/kg, sc) 15 min before the morphine challenge significantly inhibited the morphine-induced behavior sensitiza-
tion (P<0.05).
Conclusion: ATPM-ET may have potential as a therapeutic agent for the treatment of drug abuse.
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Introduction
Opioid analgesic drugs, such as morphine, are widely used for 
the relief of severe pain.  However, repeated use of morphine 
can induce tolerance and addiction (physical and psychologi-
cal dependence)
[1, 2].  Indeed, opioid addiction persists as a 
major public health problem
[3–5].  Although much progress has 
been made, therapeutic strategies for the treatment of opioid 
addiction are still limited, largely due to the poor under-
standing of the mechanisms contributing to opioid addiction.   
Hence, it is necessary to further explore the neural mecha-
nisms underlying opioid addiction and to develop new strate-
gies for the treatment of opioid abuse.
Numerous studies have suggested that the µ-opioid receptor 
plays a major role in opioid addiction, whereas κ-opioid ago-
nists may have therapeutic potential for opioid addiction.  For 
example, previous studies in both nonhuman primates and 
rats have demonstrated that κ agonists functionally attenu-
ate many of the behavioral effects of cocaine, including place 
preference
[6–8], self-administration
[9–12] and the reinstatement 
of extinguished drug-taking behavior in an animal model of 
relapse
[12, 13].  However, these selective agonists produce many 
severe, undesirable side effects such as salivation, emesis, and 
sedation in nonhuman primates
[10, 11], which may limit the 
clinical utility of κ agonists for the treatment of drug abuse.  
Increasing evidence suggests that κ agonists with mixed 
activity at κ and µ receptors may be more promising candi-
dates for drug abuse pharmacotherapy than highly selective κ 
agonists
[14, 15].  Therefore, one potential treatment strategy for 
opioid addiction is to develop compounds with mixed activity 
at κ and µ receptors
[16, 17].  A recent study from our group dem-
onstrated that ATPM, a novel mixed κ agonist and μ agonist/
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antagonist, can reduce heroin self-administration with rela-
tively low levels of sedation
[18].  The present study was under-
taken to examine the effects of ATPM-ET, a derivate of ATPM, 
on morphine-induced physical dependence and behavioral 
sensitization (Figure 1).  
Materials and methods
Cell culture and membrane preparation
CHO cells were transfected with κ-, μ-, or δ- opioid receptors 
using Lipofectamine (Invitrogen) according to the manu-
facturer’s protocol.  CHO cells stably expressing κ-, μ-, or 
δ-opioid receptors were maintained in F12 medium with 10% 
fetal calf serum and 0.25 mg/mL G418.  Cells were incubated 
in a humidified atmosphere consisting of 5% CO2 and 95% air 
at 37 °C.
Cell membranes were prepared as described in our previous 
report
[19].  Cells were detached by incubation with phosphate-
buffered saline containing 1 mmol/L EDTA and centrifuged at 
1000×g for 10 min (4 °C).  The cell pellet was suspended in ice-
cold homogenization buffer composed of 50 mmol/L HEPES, 
pH 7.4, 1 mmol/L MgCl2, and 1 mmol/L EGTA.  Cells were 
homogenized with 10 strokes using a glass Dounce homoge-
nizer.  After centrifugation at 40000×g for 10 min (4 °C), pellets 
were resuspended in homogenization buffer, homogenized, 
and centrifuged again.  The final pellets were resuspended in 
50 mmol/L Tris–HCl buffer, pH 7.4.  Protein concentration 
was determined, and aliquots were stored at -80 °C.
Competitive binding assay
Membrane proteins were incubated with varying concen-
trations of ATPM-ET in a binding buffer composed of 50 
mmol/L Tris-HCl, pH 7.5 at 25 °C.  Incubation times of 60 min 
were used for the μ-selective peptide, [
3H]DAMGO, and the 
κ-selective ligand, [
3H]U69,593.  A 3 h incubation was used 
with the δ-selective antagonist, [
3H]naltrindole.  The final con-
centrations of [
3H]DAMGO, [
3H]naltrindole, and [
3H]U69,593 
were 0.25, 0.2, and 1 nmol/L, respectively.  Nonspecific bind-
ing was measured by the inclusion of 10 μmol/L naloxone.   
The binding was terminated by filtering the samples under 
reduced pressure through GF/B filters (Whatman).  The 
bound radioactivity on each filter was determined by liquid 
scintillation counting (Beckman LS6500).
GTPγS binding assay
[
35S]GTPγS binding was performed as described previ-
ously
[19].  Briefly, membranes (15 μg/tube) were incubated 
with 0.1 nmol/L [
35S]GTPγS in a binding buffer composed of 
50 mmol/L Tris–HCl, pH 7.5, 1 mmol/L EDTA, 5 mmol/L 
MgCl2, 100 mmol/L NaCl, and 40 μmol/L GDP at 30 °C for 
1 h in the presence of increasing concentrations of ATPM-ET.   
Nonspecific binding was determined in the presence of nonra-
dioactive GTPγS (10 μmol/L).  Reactions were terminated by 
rapid filtration through GF/B filters (Whatman), and bound 
radioactivity was determined by liquid scintillation counting 
(Beckman LS6500).  
Animals
Male Kunming mice (about 20 g) were obtained from the 
Laboratory Animal Center, Chinese Academy of Sciences 
(Shanghai, China).  Mice were housed in groups of 10 and 
maintained on a 12 h light/dark cycle (lights on at 8:00 a.m.) in 
a temperature-controlled environment.  Mice were given free 
access to food and water.  All animal treatments were strictly 
in accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals.
Hot plate test
Hot plate tests were performed using a plate temperature of 
55 °C.  Mice were placed on the heated smooth surface, and the 
jumping latency or the latency to begin licking or shaking the 
limbs was measured.  Prior to drug administration, the nocice-
ptive response of each mouse was measured twice.  The aver-
age of these two responses was used as the pre-drug latency 
for each mouse.  A cut-off time of 60 s was used to minimize 
tissue damage.  Tests were performed 15 min after subcutane-
ous administration of drug.  Antinociception was calculated 
using the following formula: % antinociception=100×(test 
latency – basal latency)/(60 – basal latency).
Physical dependence assay
Physical dependence assays were performed according to our 
previously published protocols
[19].  Morphine was injected 
subcutaneously twice daily (8:30 and 16:30), and the dose was 
increased progressively from 20 to 100 mg/kg over a period of 
5 days.  Two hours following the final injection of morphine or 
ATPM-ET, withdrawal jumping was induced by subcutaneous 
injection of naloxone (3.0 mg/kg).  Immediately following the 
naloxone injection, mice were placed on a circular platform (30 
cm diameter and 70 cm height), and the jumping frequency 
of each mouse was recorded for 30 min.  Body weight was 
measured initially and at 30 and 60 min after the naloxone 
injection.  To study the effects of ATPM-ET and (−)U50,488H 
on morphine physical dependence, mice were treated with 
varying doses of ATPM-ET (0.1–2 mg/kg, subcutaneously) or 
(−)U50,488H (2 mg/kg, subcutaneously) 15 min prior to each 
morphine administration during a chronic morphine treatment 
paradigm.  To evaluate the potential of ATPM-ET to induce 
physical dependence, animals were injected with ATPM-ET 
Figure 1.  Chemical structure of ATPM-ET.1549
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twice daily with progressively increasing doses, ranging from 
0.1 to 2 mg/kg, over a period of 5 days.  Following this treat-
ment regimen, naloxone-induced withdrawal jumping was 
measured as described above.
Behavioral sensitization assay
Locomotor activity was measured by a video tracking system 
(JLBehv-LAG, Shanghai, China).  Each chamber of 26 cm×14 
cm×15 cm (length×width×height) was equipped with a video 
camera above the center of the floor.  The walls and floors 
were made of clear plastic that had been painted black.  Total 
distance traveled was recorded in cm.
Mice were treated with morphine (10 mg/kg, subcutane-
ously) or saline for 7 consecutive days, and their activity was 
measured for 1 h after drug administration on days 1, 4, and 7.   
After a 7-d washout period, mice were challenged with mor-
phine (10 mg/kg, subcutaneously), and their locomotor activ-
ity was measured for 1 h, as previously described
[20].
Four groups of mice were injected with morphine (10 
mg/kg, subcutaneously) for 7 consecutive days to induce 
behavioral sensitization, and one group of mice was injected 
with saline (10 mL/kg, subcutaneously).  After 7 days of 
washout, mice were treated with either saline or ATPM-ET 
(0.75, 1.5, 3 mg/kg, subcutaneously) 15 min prior to morphine 
challenge (10 mg/kg, subcutaneously).  The locomotor activity 
of the mice was then measured for 1 h.  
Drugs
[
35S]GTPγS (1030 Ci/mmol) was purchased from Amersham 
Biosciences (Piscataway, NJ).  (−)U50,488H, naloxone, GTPγS, 
and GDP were supplied by Sigma-Aldrich (St Louis, MO).   
Morphine was obtained from the National Institute of Forensic 
Science (Beijing, China).  ATPM-ET was synthesized by Prof 
Ao ZHANG in our institute.  ATPM-ET and U50,488H were 
dissolved in saline.
Statistical analysis
The data are expressed as means±SEM.  Statistical analyses 
were performed using one-way ANOVAs and LSD post hoc 
tests.  P-values less than 0.05 were considered statistically 
significant.  When only two groups were compared, statistical 
significance was determined by an unpaired Student t test.
Results
Affinity, selectivity, and agonist activity of ATPM-ET
The binding affinity of ATPM-ET to μ-, δ-, and κ-opioid recep-
tors was determined using competitive binding assays.  As 
shown in Table 1, ATPM-ET exhibited a high affinity to both 
κ- and µ-opioid receptors with Ki values of 0.15 nmol/L and 
4.7 nmol/L, respectively.  The affinity to the κ-opioid recep-
tor is 31-fold higher than the affinity to the µ-opioid recep-
tor, indicting that ATPM-ET has a high selectivity for κ- over 
µ-opioid receptors.  However, ATPM-ET exhibited a 287-fold 
lower affinity to the δ-opioid receptor (Ki of 43 nmol/L) than 
to the κ-opioid receptor.  
To characterize the agonist activity of ATPM-ET, [
35S]GTPγS 
assays were performed with membranes prepared from CHO 
cells that had been stably transfected with either the κ- or the 
µ-opioid receptors.  The maximal stimulatory response of 
(–)U50,488H and DAMGO was designated as the 100% effect 
for κ- and μ-opioid receptors, respectively.  ATPM-ET pro-
duced a maximal stimulation (Emax) of 85% for the κ-opioid 
receptor and 36% for the µ-opioid receptor and exhibited an 
EC50 value of 1.7 nmol/L for the κ- and 61 nmol/L for the 
µ-opioid receptors (Table 1).  The results of these [
35S]GTPγS 
binding assays indicate that ATPM-ET acts as a high-efficacy 
κ-opioid receptor agonist and a low-efficacy µ-opioid receptor 
agonist.
The antinociceptive effect of ATPM-ET 
Activation of opioid receptors can produce antinociceptive 
effects against noxious stimuli, such as heat.  Therefore, the 
antinociceptive effects of ATPM-ET in mice were studied 
using the hot plate test.  As shown in Table 2, subcutaneous 
administration of ATPM-ET produced a dose-dependent 
antinociceptive effect, with an ED50 value of 2.68 (2.34–3.07) 
mg/kg in the hot plate test.  Morphine and (–)U50,488H also 
resulted in a dose-dependent antinociceptive effect in the hot 
plate assay, with ED50 values of 4.42 (2.51–7.75) mg/kg and 
6.95 (5.68–8.50) mg/kg, respectively.
The effect of ATPM-ET on morphine physical dependence
Withdrawal jumping is a widely used and highly reliable 
index of opiate withdrawal behavior.  We evaluated the effects 
of ATPM-ET on morphine dependence by measuring with-
drawal jumping and loss of body weight.  An acute injection of 
Table 1.  Binding affinities for opioid receptors and efficacy in stimulating [
35S]GTPγS binding to membranes of ATPM-ET in CHO cells stably expressing 
opioid receptors. Data are expressed as the mean±SEM of independent experiments performed in triplicate.  
                                                                        Receptor binding                                                                                       GTPγS binding
                                 Ki±SEM (nmol/L)                   Selectivity                    κ                                                μ
Compound
          [
3H]DAMGO     [
3H]Naltrindole     [
3H]U69,593
                                  (μ)                      (δ)                   (κ)           
μ/κ
               
δ/κ
 
Emax (%)        EC50 (nmol/L)        Emax (%)      EC50 (nmol/L) 
 
ATPM-ET  4.7±0.9  43±8  0.15±0.05    31  290   85±9  1.7±0.2   36±7  61±81550
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naloxone (3.0 mg/kg, sc) resulted in a robust increase in with-
drawal jumping following repeated treatment of morphine for 
5 consecutive days in mice compared to repeated treatment 
with saline (Figure 2A).  Administration of ATPM-ET (1, 2 
mg/kg, subcutaneously) prior to naloxone injection signifi-
cantly inhibited withdrawal jumping.  In addition, ATPM-ET 
(1, 2 mg/kg, subcutaneously) also showed a trend toward 
decreasing morphine withdrawal-induced weight loss (Figure 
2B).  In agreement with previous studies
[21], administration of 
(−)U50,488H (2 mg/kg, sc) did not inhibit naloxone-precipi-
tated jumping or loss of body weight.  Moreover, administra-
tion of ATPM-ET alone for 5 days did not induce morphine-
like dependence after naloxone precipitation, which suggested 
that ATPM-ET has a lower abuse potential than morphine 
(Figure 2).
The effect of ATPM-ET on morphine-induced behavioral 
sensitization
It has been reported previously that behavioral sensitization 
is involved in opioid addiction and that κ-opioid agonists 
can attenuate many of the behavioral effects induced by opi-
ates
[21–23].  As a result, we decided to investigate the effects of 
ATPM-ET on morphine-induced behavioral sensitization.  
First, we established the induction of morphine sensitization 
in mice as described previously
[24].  Mice were treated with 
saline or morphine (10 mg/kg, sc) once per day for 7 consecu-
tive days.  Locomotor activity was recorded for 1 h following 
drug administration on days 1, 4, and 7.  As shown in Figure 
3, the initial injection of morphine (10 mg/kg, subcutaneously) 
elicited a significant increase in locomotor activity when com-
pared to an injection of saline.  Daily morphine injections led 
to a progressive increase in locomotor activity, with signifi-
cantly elevated locomotion on days 4 and 7 compared to day 
1.  A two-factor repeated measures ANOVA shows significant 
effects of both drug (F(1, 28)=211.2, P<0.001) and time of treat-
ment (F(2, 28)=6.82, P<0.001) as well as an interaction between 
the drug and the time of treatment (F(2, 28)=7.05, P<0.001).  In 
contrast, no enhancement of locomotor activity was observed 
in mice injected with saline for 7 days.  These results indicate 
that morphine promotes the development of behavioral sensi-
tization in mice, consistent with previous studies
[24].  
Next, we examined the effects of ATPM-ET on morphine-
induced behavioral sensitization.  After 7 days of washout, 
challenge with morphine (10 mg/kg, subcutaneously) induced 
a robust increase in locomotor activity in mice repeatedly 
treated with morphine (10 mg/kg) for 7 consecutive days 
compared to mice repeatedly injected with saline (P<0.01).   
Figure 2.  Effects of ATPM-ET and (–)U50,488H on naloxone-precipitated 
jumping and body weight loss in mice treated chronically with morphine.   
Mice were treated with progressively increasing doses of either ATPM-
ET or morphine alone or treated with progressively increasing doses of 
morphine concomitantly with ATPM-ET (0.1–2 mg/kg, subcutaneously) or 
(-)U50,488H (2 mg/kg, subcutaneously) for 5 days.  Morphine withdrawal 
jumping and body weight loss were precipitated by naloxone (3 mg/kg, 
subcutaneously).  (A) The number of jumping events was measured for 30 
min after naloxone injection.  (B) Body weight loss was measured initially 
and 30 and 60 min after the naloxone injection.  Data were presented as 
the mean±SEM from 10 animals.  
bP<0.05, 
cP<0.01 vs morphine alone.
Figure 3.  The induction of morphine sensitization in mice.  Two groups 
were given morphine (10 mg/kg, subcutaneously) or saline (10 mL/kg, 
subcutaneously) for 7 consecutive days and their activity was measured 
for 1 h after each administration of drug (or saline) on days 1, 4, and 
7.  Data are shown as means±SEM.  (n=10 per group).  
bP<0.05, 
cP<0.01 
vs the corresponding saline group.  
eP<0.05, 
fP<0.01 vs the first 
administration  group.
Table 2.  ED50 values and 95% confidence limits of the antinociception 
produced by subcutaneous injection of ATPM-ET, morphine and (–)50,488H 
in hot plate test. The antinociceptive ED50 value of each drug was 
calculated from data obtained at 15 min after sc administration of each 
dose of compounds and for each dose at least 10 mice were used.
    
Compound
                                  Hot plate test
                               ED50 (mg/kg, sc)           95% Confidence limits                                                               
 
  (–)U50,488H  6.95  (5.68–8.50)
  Morphine  4.42  (2.51–7.75)
  ATPM-ET  2.68  (2.34–3.07)  1551
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One-way ANOVA revealed a significant effect of ATPM-ET on 
the expression of morphine sensitization (F(4, 37)=6.42, P<0.01).   
LSD post hoc tests indicated that treatment with ATPM-ET (1.5, 
3 mg/kg, subcutaneously) 15 min before the morphine chal-
lenge significantly inhibited morphine-induced behavior sen-
sitization (Figure 4, P<0.05).
Discussion
A great deal of research has focused on κ-opioid receptor 
agonists with activity at the μ-opioid receptor as potential 
compounds to treat drug addiction
[25, 26].  It has been reported 
that compounds with mixed κ and μ activity decrease cocaine 
self-administration
[27–29].  These findings suggest that κ ago-
nists with μ-receptor activity may be promising medications 
for drug addiction.  To further confirm the effects of κ-opioid 
agonists with activity at the μ-opioid receptor on drug addic-
tion, we investigated the effects of ATPM-ET, an N-ethyl 
substituted aminothiazolomorphinan, on morphine physical 
dependence and the expression of morphine-induced behav-
ioral sensitization in mice.
Our current results demonstrate that ATPM-ET is a full κ 
agonist with partial μ agonist activity and that ATPM-ET dis-
plays a potent antinociceptive effect in mice in the hot plate 
test.  The results from this study also show that the adminis-
tration of ATPM-ET to chronic morphine-treated mice prior to 
naloxone precipitation significantly inhibits jumping and body 
weight loss induced by morphine withdrawal.  However, con-
sistent with previous studies
[19, 21], the classic κ1-opioid recep-
tor agonist, (–)U50,488H, failed to inhibit withdrawal jumping 
and body weight loss induced by naloxone precipitation.  Our 
findings support the hypothesis that κ agonists with partial μ 
agonist activity may have greater therapeutic benefits in the 
treatment of drug addiction.  
Acute or repeated morphine administration in rodents can 
enhance locomotor activity and cause behavioral sensitization, 
a long-lasting behavioral alteration that has been proposed to 
play a prominent role in some of the motivational aspects of 
drug addiction, such as craving and drug-seeking
[30].  Consis-
tent with previous studies
[31–33], we demonstrate that repeated 
administration of morphine can increase locomotor activity 
and induce behavioral sensitization.  To further confirm that 
ATPM-ET may have utility for the treatment of drug abuse, 
we examined the effects of ATPM-ET on morphine-induced 
behavioral sensitization.  The present study demonstrates that 
ATPM-ET dose-dependently inhibits the expression of behav-
ioral sensitization induced by morphine treatment, which 
further supports that ATPM-ET may be a promising candidate 
agent for the treatment of drug abuse.
In conclusion, ATPM-ET is a new aminothiazolomorphinan 
analog with mixed κ agonist and μ agonist activities that pro-
duces dose-dependent antinociception in the hot plate test.   
More importantly, ATPM-ET can attenuate morphine-induced 
physical dependence and inhibit morphine-induced behav-
ioral sensitization.  Thus, ATPM-ET is a potentially promising 
candidate for the treatment of opioid addiction.
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